Hepatitis C Information - Coley Pharmaceutical Group Reports Fourth Quarter and Full Year 2005 Financial Results

Coley Pharmaceutical Group Reports Fourth Quarter and Full Year 2005 Financial Results
[Press Release] PR Newswire via Yahoo! Finance - Feb 23 5:31 AM
Coley Pharmaceutical Group, Inc. , a biopharmaceutical company discovering and developing a novel class of drug candidates known as TLR Therapeutics, today reported its financial results for the quarter and year ended December 31, 2005.Save to My Web

XTL Biopharmaceuticals to Present at the JPMorgan Small Cap Conference
RedNova - Feb 13 2:30 AM
NEW YORK, February 13 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals, Ltd. , a biopharmaceutical company developing drugs against hepatitis, announced today that Ron Bentsur, Chief Executive Officer, will present an overview of the Company at The JPMorgan Small Cap Conference in Philadelphia.Save to My Web

Nabi Biopharmaceuticals to Present at the Lehman Brothers Ninth Annual Global Healthcare Conference
RedNova - Mar 03 7:30 AM
BOCA RATON, Fla., March 3 /PRNewswire-FirstCall/ -- Nabi Biopharmaceuticals announced today that Thomas H.Save to My Web

Novelos Therapeutics Closes $15 Million Private Placement
RedNova - Mar 07 8:45 PM
Novelos Therapeutics, Inc. (OTCBB: NVLT), a bioSave to My Web

Novelos Therapeutics Files SPA with FDA for Phase 3 Development in Lung Cancer
[Press Release] Business Wire via Yahoo! Finance - Mar 08 5:30 AM
NEWTON, Mass.----March 8, 2006--Novelos Therapeutics, Inc. , a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that it has filed a Special Protocol Assessment with the Food and Drug Administration for a single pivotal Phase 3 trial in advanced non-small cell lung cancer, for its lead product NOV-002 in combination with first-line Save to My Web